Previous close | 0.1050 |
Open | 0.1050 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.1050 - 0.1050 |
52-week range | 0.1000 - 0.4497 |
Volume | |
Avg. volume | 954 |
Market cap | 10.359M |
Beta (5Y monthly) | 2.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2300 |
Earnings date | 11 Jun 2024 - 17 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting").
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company's Board of Directors.